Key result
Elevated plasma levels of asymmetric dimethylarginine (ADMA) act as an endogenous nitric oxide synthase inhibitor and may serve as a missing link between cardiovascular disease and chronic kidney disease.
Answers are grounded in this paper and cite their sources.
Elevated ADMA levels may explain the pathophysiological link between chronic kidney disease and increased cardiovascular risk through impaired nitric oxide bioavailability.
Decreased nitric oxide (NO) production and/or impaired NO bioavailability may occur in patients with chronic kidney disease (CKD), and could contribute to the elevation of blood pressure, cardiovascular disease (CVD) and the progression of renal injury in these patients. However, the underlying molecular mechanisms for reduced NO action in patients with CKD remains to be elucidated. Asymmetric dimethylarginine (ADMA) is a naturally occurring L-arginine analogue found in plasma and various types of tissues, acting as an endogenous NO synthase inhibitor in vivo. Further, plasma level of ADMA is elevated in patients with CKD and found to be a strong biomarker or predictor for future cardiovascular events. In addition, plasma level of ADMA could predict the progression of renal injury in these patients as well. These findings suggest that elevation of ADMA may be a missing link between CVD and CKD. In this review, we discuss the molecular mechanisms for the elevation of ADMA and its pathophysiological role for CVD in high-risk patients, especially focusing on patients with CKD.
No takes yet. Share an insight, caveat, or question.
Ueda et al. (2007) conducted a review in Chronic kidney disease and cardiovascular disease. Asymmetric dimethylarginine (ADMA) was evaluated. Elevated plasma levels of asymmetric dimethylarginine (ADMA) act as an endogenous nitric oxide synthase inhibitor and may serve as a missing link between cardiovascular disease and chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: